2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T9f8,Medication nonadherence contributes to vision loss from glaucoma, a leading cause of irreversible blindness in the US. Intervention to improve adherence can benefit health outcomes and quality of life, while reducing health system and public health burden. To compare the Support, Educate, Empower (SEE) intervention with standard written education on glaucoma medication adherence. The SEE study was a parallel, nonmasked, 1:1 randomized clinical trial testing intervention superiority. Participants were recruited from the University of Michigan (UM) and Henry Ford Health System (HFHS) between April 27, 2021, and December 18, 2023. Adults with glaucoma taking 1 or more ocular hypotensive eye drop medications who self-reported adherence of 85% or lower were eligible. The SEE intervention is a 6-month motivational interviewing-based glaucoma health coaching program administered by a nonphysician counselor, including 3 in-person sessions, 4 between-visit phone calls, personalized multimedia glaucoma education, and automated medication reminders. The control consisted of usual care and 3 mailings of standard written glaucoma education. Medication adherence (primary outcome) was electronically monitored (AdhereTech) and calculated as the percentage of doses taken on time divided by those prescribed over the 6-month study period. Change in glaucoma-related distress (secondary outcome) was also investigated. Of 236 participants enrolled (108 in UM and 128 in HFHS), 235 (mean [SD] age, 67.3 [10.9] years; 124 [53%] female) were randomized to the SEE intervention (n = 117) or control (n = 118). Participant characteristics were balanced between groups. Mean (SD) self-reported adherence was 63.9% (17.9%). Medication adherence was significantly better in the SEE intervention group compared with that among control participants (mean [SD], 77.6% [19.7%]; n = 113 vs 58.0% [25.2%]; n = 114; difference, 19.7%; 95% CI, 13.7 to 25.6; P < .001), and more achieved 80% or greater adherence (62 of 113 [54.9%] vs 27 of 114 [23.7%]; P < .001). The difference in change in glaucoma-related distress between intervention and control was -0.3 (95% CI, -0.5 to -0.1) after adjusting for baseline distress. The SEE glaucoma coaching program improved glaucoma medication adherence and reduced glaucoma-related distress compared with standard written education. The SEE program represents an evidence-based method to improve medication adherence necessary to improve glaucoma outcomes. ClinicalTrials.gov Identifier: NCT04735653.31:T10b7, Importance Medication nonadherence contributes to vision loss from glaucoma, a leading cause of irreversible blindness in the US. Intervention to improve adherence can benefit health outcomes and quality of life, while reducing health system and public health burden. Objective To compare the Support, Educate, Empower (SEE) intervention with standard written education on glaucoma medication adherence. Design, Setting, and Participants The SEE study was a parallel, nonmasked, 1:1 randomized clinical trial testing intervention superiority. Participants were recruited from the University of Michigan (UM) and Henry Ford Health System (HFHS) between April 27, 2021, and December 18, 2023. Adults with glaucoma taking 1 or more ocular hypotensive eye drop medications who self-reported adherence of 85% or lower were eligible. Intervention The SEE intervention is a 6-month motivational interviewing-based glaucoma health coaching program administered by a nonphysician counselor, including 3 in-person sessions, 4 between-visit phone calls, personalized multimedia glaucoma education, and automated medication reminders. The control consisted of usual care and 3 mailings of standard written glaucoma education. Main Outcomes and Measures Medication adherence (primary outcome) was electronically monitored (AdhereTech) and calculated as the percentage of doses taken on time divided by those prescribed over the 6-month study period. Change in glaucoma-related distress (secondary outcome) was also investigated. Results Of 236 participants enrolled (108 in UM and 128 in HFHS), 235 (mean [SD] age, 67.3 [10.9] years; 124 [53%] female) were randomized to the SEE intervention (n = 117) or control (n = 118). Participant characteristics were balanced between groups. Mean (SD) self-reported adherence was 63.9% (17.9%). Medication adherence was significantly better in the SEE intervention group compared with that among control participants (mean [SD], 77.6% [19.7%]; n = 113 vs 58.0% [25.2%]; n = 114; difference, 19.7%; 95% CI, 13.7 to 25.6; P &lt; .001), and more achieved 80% or greater adherence (62 of 113 [54.9%] vs 27 of 114 [23.7%]; P &lt; .001). The difference in change in glaucoma-related distress between intervention and control was −0.3 (95% CI, −0.5 to −0.1) after adjusting for baseline distress. Conclusions and Relevance The SEE glaucoma coaching program improved glaucoma medication adherence and reduced glaucoma-related distress compared with standard written education. The SEE program represents an evidence-based method to improve medication adherence necessary to improve glaucoma outcomes. Trial Registration ClinicalTrials.gov Identifier: NCT04735653 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Health Coaching / Behavioral Intervention: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Health Coaching / Behavioral Intervention (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Health%20Coaching%20%2F%20Behavioral%20Intervention\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Health Coaching / Behavioral Intervention\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Health%20Coaching%20%2F%20Behavioral%20Intervention\"}]}}"}}]],["$","$L2f",null,{"title":"Health Coaching / Behavioral Intervention: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Health Coaching / Behavioral Intervention — concise summaries and practical next steps.","papers":[{"doi":"10.1001/jamaophthalmol.2026.0001","pmid":"41746659","title":"Effect of the Support, Educate, Empower Personalized Glaucoma Coaching Program on Medication Adherence","journal_title":"JAMA Ophthalmology","journal_issn":"2168-6165","published_at":"2026-02-26T00:00:00.000Z","url":"https://doi.org/10.1001/jamaophthalmol.2026.0001","source_score":35,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-04-19","doi":"10.1001/jamaophthalmol.2026.0001","days":"30","issn":"2168-6165","rank":"5","field":"Clinical Medicine","score":"35","category":"Ophthalmology","categories":["Ophthalmology"],"_categories":["Ophthalmology"]},"pubmed":{"doi":"10.1001/jamaophthalmol.2026.0001","title":"Effect of the Support, Educate, Empower Personalized Glaucoma Coaching Program on Medication Adherence: The SEE Program Randomized Clinical Trial.","journal":"JAMA ophthalmology","methods":"","results":"Of 236 participants enrolled (108 in UM and 128 in HFHS), 235 (mean [SD] age, 67.3 [10.9] years; 124 [53%] female) were randomized to the SEE intervention (n = 117) or control (n = 118). Participant characteristics were balanced between groups. Mean (SD) self-reported adherence was 63.9% (17.9%). Medication adherence was significantly better in the SEE intervention group compared with that among control participants (mean [SD], 77.6% [19.7%]; n = 113 vs 58.0% [25.2%]; n = 114; difference, 19.7%; 95% CI, 13.7 to 25.6; P < .001), and more achieved 80% or greater adherence (62 of 113 [54.9%] vs 27 of 114 [23.7%]; P < .001). The difference in change in glaucoma-related distress between intervention and control was -0.3 (95% CI, -0.5 to -0.1) after adjusting for baseline distress.","abstract":"$30","keywords":[],"pubmed_id":"41746659","conclusions":"","publication_date":"2026-02-26T00:00:00"},"crossref":{"DOI":"10.1001/jamaophthalmol.2026.0001","URL":"https://doi.org/10.1001/jamaophthalmol.2026.0001","ISSN":["2168-6165"],"link":[{"URL":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2845609/jamaophthalmology_newmancasey_2026_oi_260001_1776173512.61667.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"299","type":"journal-article","issue":"4","score":1,"title":["Effect of the Support, Educate, Empower Personalized Glaucoma Coaching Program on Medication Adherence"],"author":[{"given":"Paula Anne","family":"Newman-Casey","sequence":"first","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor"}]},{"given":"Leslie M.","family":"Niziol","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor"}]},{"given":"Ming-Chen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor"}]},{"given":"Deborah","family":"Darnley-Fisch","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Henry Ford Health System, Detroit, Michigan"}]},{"given":"Nauman","family":"Imami","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Henry Ford Health System, Detroit, Michigan"}]},{"given":"Jamie","family":"Mitchell","sequence":"additional","affiliation":[{"name":"School of Social Work, University of Michigan, Ann Arbor"}]},{"given":"Chamisa","family":"MacKenzie","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor"}]},{"given":"Michele","family":"Heisler","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Michigan, Ann Arbor"},{"name":"Department of Health Behavior and Health Equity, School of Public Health, University of Michigan, Ann Arbor"}]}],"issued":{"date-parts":[[2026,4,1]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":"144","created":{"date-time":"2026-02-26T16:30:25Z","timestamp":1772123425000,"date-parts":[[2026,2,26]]},"indexed":{"date-time":"2026-04-17T04:11:01Z","timestamp":1776399061119,"date-parts":[[2026,4,17]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2845609"}},"subtitle":["The SEE Program Randomized Clinical Trial"],"deposited":{"date-time":"2026-04-16T15:00:31Z","timestamp":1776351631000,"date-parts":[[2026,4,16]]},"issn-type":[{"type":"print","value":"2168-6165"}],"published":{"date-parts":[[2026,4,1]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.5888/pcd17.200130","key":"eoi260001r1","year":"2020","issue":null,"author":"Boersma","volume":"17","first-page":null,"unstructured":null,"article-title":"Prevalence of multiple chronic conditions among US adults, 2018.","journal-title":"Prev Chronic Dis","doi-asserted-by":"publisher"},{"DOI":"10.1167/iovs.12-9483d","key":"eoi260001r5","year":"2012","issue":"5","author":"Vajaranant","volume":"53","first-page":"2464","unstructured":null,"article-title":"A 40-year forecast of the demographic shift in primary open-angle glaucoma in the United States.","journal-title":"Invest Ophthalmol Vis Sci","doi-asserted-by":"publisher"},{"DOI":"10.1001/archopht.124.12.1754","key":"eoi260001r6","year":"2006","issue":"12","author":"Rein","volume":"124","first-page":"1754","unstructured":null,"article-title":"The economic burden of major adult visual disorders in the United States.","journal-title":"Arch Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2019.10.022","key":"eoi260001r7","year":"2020","issue":"4","author":"Newman-Casey","volume":"127","first-page":"477","unstructured":null,"article-title":"The association between medication adherence and visual field progression in the collaborative initial glaucoma treatment study.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1097/IJG.0000000000001943","key":"eoi260001r8","year":"2021","issue":"12","author":"Shu","volume":"30","first-page":"1047","unstructured":null,"article-title":"Topical medication adherence and visual field progression in open-angle glaucoma: analysis of a large US health care system.","journal-title":"J Glaucoma","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ogla.2021.04.006","key":"eoi260001r9","year":"2022","issue":"1","author":"Muir","volume":"5","first-page":"40","unstructured":null,"article-title":"Improved glaucoma medication adherence in a randomized controlled trial.","journal-title":"Ophthalmol Glaucoma","doi-asserted-by":"publisher"},{"DOI":"10.1097/IJG.0000000000000431","key":"eoi260001r10","year":"2016","issue":"10","author":"Killeen","volume":"25","first-page":"815","unstructured":null,"article-title":"User-centered design of the eyeGuide: a tailored glaucoma behavior change program.","journal-title":"J Glaucoma","doi-asserted-by":"publisher"},{"DOI":"10.1177/17407745221136571","key":"eoi260001r11","year":"2023","issue":"2","author":"Newman-Casey","volume":"20","first-page":"192","unstructured":null,"article-title":"The Support, Educate, Empower personalized glaucoma coaching trial design.","journal-title":"Clin Trials","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2013.01.002","key":"eoi260001r12","year":"2013","issue":"7","author":"Chang","volume":"120","first-page":"1396","unstructured":null,"article-title":"Development and validation of a predictive model for nonadherence with once-daily glaucoma medications.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ogla.2021.07.012","key":"eoi260001r13","year":"2022","issue":"2","author":"Cho","volume":"5","first-page":"137","unstructured":null,"article-title":"Comparison of medication adherence assessment tools to identify glaucoma medication nonadherence.","journal-title":"Ophthalmol Glaucoma","doi-asserted-by":"publisher"},{"DOI":"10.1016/0021-9681(87)90171-8","key":"eoi260001r14","year":"1987","issue":"5","author":"Charlson","volume":"40","first-page":"373","unstructured":null,"article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.","journal-title":"J Chronic Dis","doi-asserted-by":"publisher"},{"DOI":"10.1186/s40814-018-0320-6","key":"eoi260001r15","year":"2018","issue":null,"author":"Newman-Casey","volume":"4","first-page":"128","unstructured":null,"article-title":"Personalized behavior change program for glaucoma patients with poor adherence: a pilot interventional cohort study with a pre-post design.","journal-title":"Pilot Feasibility Stud","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ogla.2020.04.016","key":"eoi260001r16","year":"2020","issue":"4","author":"Hollenhorst","volume":"3","first-page":"238","unstructured":null,"article-title":"Patient experience during the support, educate, empower glaucoma coaching program to improve medication adherence: a pilot study.","journal-title":"Ophthalmol Glaucoma","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ogla.2020.04.013","key":"eoi260001r17","year":"2020","issue":"4","author":"Newman-Casey","volume":"3","first-page":"228","unstructured":null,"article-title":"The impact of the support, educate, empower personalized glaucoma coaching pilot study on glaucoma medication adherence.","journal-title":"Ophthalmol Glaucoma","doi-asserted-by":"publisher"},{"DOI":"10.1080/10410236.2018.1557357","key":"eoi260001r19","year":"2020","issue":"2","author":"Newman-Casey","volume":"35","first-page":"233","unstructured":null,"article-title":"A glaucoma-specific brief motivational interviewing training program for ophthalmology para-professionals: assessment of feasibility and initial patient impact.","journal-title":"Health Commun","doi-asserted-by":"publisher"},{"DOI":"10.2337/diacare.28.3.626","key":"eoi260001r20","year":"2005","issue":"3","author":"Polonsky","volume":"28","first-page":"626","unstructured":null,"article-title":"Assessing psychosocial distress in diabetes: development of the diabetes distress scale.","journal-title":"Diabetes Care","doi-asserted-by":"publisher"},{"DOI":"10.1159/000512924","key":"eoi260001r21","year":"2021","issue":"3","author":"Kolli","volume":"64","first-page":"524","unstructured":null,"article-title":"The minimal clinically important difference in glaucoma medication adherence: interviews of glaucoma experts.","journal-title":"Ophthalmic Res","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamanetworkopen.2023.42950","key":"eoi260001r22","year":"2023","issue":"11","author":"Banks","volume":"6","first-page":null,"unstructured":null,"article-title":"Ascertainment of minimal clinically important differences in the Diabetes Distress Scale–17: a secondary analysis of a randomized clinical trial.","journal-title":"JAMA Netw Open","doi-asserted-by":"publisher"},{"DOI":"10.2337/dc11-1572","key":"eoi260001r23","year":"2012","issue":"2","author":"Fisher","volume":"35","first-page":"259","unstructured":null,"article-title":"When is diabetes distress clinically meaningful?: establishing cut points for the Diabetes Distress Scale.","journal-title":"Diabetes Care","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2011.01.047","key":"eoi260001r24","year":"2011","issue":"9","author":"Musch","volume":"118","first-page":"1766","unstructured":null,"article-title":"Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1136/bjo.76.5.280","key":"eoi260001r25","year":"1992","issue":"5","author":"David","volume":"76","first-page":"280","unstructured":null,"article-title":"Diurnal intraocular pressure variations: an analysis of 690 diurnal curves.","journal-title":"Br J Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ophtha.2022.06.025","key":"eoi260001r26","year":"2022","issue":"11","author":"Ha","volume":"129","first-page":"1294","unstructured":null,"article-title":"Interventions for glaucoma medication adherence improvement: a network meta-analysis of randomized controlled trials.","journal-title":"Ophthalmology","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40258-019-00497-0","key":"eoi260001r27","year":"2019","issue":"6","author":"Bilger","volume":"17","first-page":"841","unstructured":null,"article-title":"Using adherence-contingent rebates on chronic disease treatment costs to promote medication adherence: results from a randomized controlled trial.","journal-title":"Appl Health Econ Health Policy","doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1755-3768.2012.02571.x","key":"eoi260001r28","year":"2013","issue":"7","author":"Beckers","volume":"91","first-page":"610","unstructured":null,"article-title":"Adherence improvement in Dutch glaucoma patients: a randomized controlled trial.","journal-title":"Acta Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1186/1471-2415-14-32","key":"eoi260001r29","year":"2014","issue":"1","author":"Cate","volume":"14","first-page":"32","unstructured":null,"article-title":"Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (the Norwich Adherence Glaucoma Study).","journal-title":"BMC Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1001/archophthalmol.2010.351","key":"eoi260001r30","year":"2011","issue":"2","author":"Muir","volume":"129","first-page":"243","unstructured":null,"article-title":"Glaucoma medication adherence: room for improvement in both performance and measurement.","journal-title":"Arch Ophthalmol","doi-asserted-by":"publisher"},{"DOI":"10.1136/bmj.38875.675486.55","key":"eoi260001r31","year":"2006","issue":"7557","author":"Simpson","volume":"333","first-page":"15","unstructured":null,"article-title":"A meta-analysis of the association between adherence to drug therapy and mortality.","journal-title":"BMJ","doi-asserted-by":"publisher"},{"DOI":null,"key":"eoi260001r4","year":"2011","issue":null,"author":"Committee on Living Well with Chronic Disease","volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"eoi260001r2","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"US Centers for Disease Control and Prevention. Fast facts: health and economic costs of chronic conditions. chronic disease. December 10, 2024. Accessed December 3, 2024. https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"eoi260001r3","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Minesota Department of Health. Treated chronic disease prevalence and spending in Minnesota. December 2022. Accessed June 10, 2025. https://www.health.state.mn.us/data/economics/docs/chroncondbrief121322.pdf","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":null,"key":"eoi260001r18","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"MINT. Welcome to the motivational interviewing website! Accessed June 10, 2025. https://motivationalinterviewing.org/","article-title":null,"journal-title":null,"doi-asserted-by":null}],"short-title":[],"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Ophthalmology"],"published-print":{"date-parts":[[2026,4,1]]},"reference-count":31,"published-online":null,"references-count":31,"short-container-title":["JAMA Ophthalmol"],"is-referenced-by-count":1},"unpaywall":{"doi":"10.1001/jamaophthalmol.2026.0001","is_oa":true,"title":"Effect of the Support, Educate, Empower Personalized Glaucoma Coaching Program on Medication Adherence","updated":"2026-03-01T09:08:15+00:00","published_date":"2026-02-26","best_oa_location":{"url":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2845609/jamaophthalmology_newmancasey_2026_oi_260001_1771607645.09787.pdf","pmh_id":null,"url_for_pdf":"https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2845609/jamaophthalmology_newmancasey_2026_oi_260001_1771607645.09787.pdf","url_for_landing_page":"https://doi.org/10.1001/jamaophthalmol.2026.0001"}}},"created_at":"2026-05-07T22:49:13.222Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"category","value":"Ophthalmology","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"condition","value":"Glaucoma","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"modality","value":"Health Coaching / Behavioral Intervention","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"modality","value":"Motivational Interviewing","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"sample_size","value":"n=235","value_numeric":235},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"warning","value":"The mean age was 67.3 years and recruitment was limited to two Michigan health systems, so generalizability to younger or more diverse populations is uncertain.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"warning","value":"The paper's DOI suggests a 2026 publication date, which is consistent with today's date — this is a recently published trial and has not yet been subject to independent replication.","value_numeric":null},{"paper_doi":"10.1001/jamaophthalmol.2026.0001","tag_type":"warning","value":"The trial was nonmasked (open-label); participant and counselor awareness of group assignment may have introduced performance or reporting bias.","value_numeric":null}],"summaries":{"what_studied":"A parallel 1:1 RCT compared the 6-month SEE motivational interviewing-based glaucoma coaching program (3 in-person sessions, 4 phone calls, personalized multimedia education, automated reminders) vs. standard written education in 235 adults with glaucoma who self-reported ≤85% medication adherence, recruited from two US health systems (April 2021–December 2023).","key_result":"Electronically monitored adherence was significantly higher in the SEE group vs. control (77.6% vs. 58.0%; difference 19.7%, 95% CI 13.7–25.6; P < .001); more SEE participants reached ≥80% adherence (54.9% vs. 23.7%, P < .001). Glaucoma-related distress also improved more with SEE (adjusted difference −0.3, 95% CI −0.5 to −0.1).","limitations":"- Trial was nonmasked (open-label), introducing potential performance and detection bias.\n- Participants were recruited from only two academic/health system sites in Michigan, which may limit generalizability.\n- Eligibility required self-reported nonadherence ≤85%, so findings may not apply to all glaucoma patients.","practice_takeaway":"Consider referring nonadherent glaucoma patients to a structured coaching program like SEE — it nearly doubled the proportion achieving ≥80% adherence compared to written education alone. The program uses nonphysician counselors, making it feasible to integrate into existing clinic workflows."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Health Coaching / Behavioral Intervention"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Health Coaching / Behavioral Intervention"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Health Coaching / Behavioral Intervention"}}}]]

Papers